Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Status Recruiting

Clinical Trial Summary

Clinical Trial Description

In recurrent advanced cervical cancer, patients were prone to drug resistance who have relapsed within prior platinum-based chemotherapy. However, immune checkpoint inhibitor's combination therapy has become a promising strategy for advanced cervical cancer. Epidermal Growth Factor Receptor (EGFR) is overexpressed in cervical cancer cells. Stereotactic radiotherapy (SBRT) can enhance the efficacy of immunotherapy. Nituzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor. Serplulimab is a fully humanized, high-affinity monoclonal antibody against programmed cell death-1 (PD-1). This phase II, single-arm study aims to evaluate the efficacy and safety of Nituzumab plus Serplulimab combined with SBRT in patients with recurrent advanced cervical cancer. Patients who have failed in standard chemotherapy，histopathologically confirmed recurrent advanced squamous cell cervical carcinoma regardless of programmed cell death-Ligand 1 (PD-L1) expression. Patients who have achieved the response state or come to stably at least six months after immunotherapy were allowed. There was at least one lesion for SBRT in addition to target lesions. ECOG 0-1 were considered eligible for enrollment. Nituzumab was given intravenously (400mg qw, 21 days per cycle), and Serplulimab was administered intravenously (200mg once every 3 weeks).The dose was 30-50 Gy in three to five fractions and the number of lesions was no more than four by SBRT. The treatment was continued until disease progression, death or intolerant toxicity. The primary endpoint was objective response rate (ORR) and the secondary endpoints included disease control rate (DCR), progression free survival (PFS), overall survival (OS) and safety. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06455072
Study type	Interventional
Source	Fujian Cancer Hospital
Contact	Qin Xu
Phone	+8613950419396
Email	1379423879@qq.com
Status	Recruiting
Phase	Phase 2
Start date	February 1, 2023
Completion date	January 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06223308` - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03367871` - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer	Phase 2
Active, not recruiting	`NCT04537156` - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	Phase 3
Recruiting	`NCT03668639` - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin	Phase 2/Phase 3
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Withdrawn	`NCT04806945` - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer	Phase 3
Active, not recruiting	`NCT04185389` - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn	`NCT03007771` - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia	Phase 1
Completed	`NCT03384511` - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Phase 4
Recruiting	`NCT05107674` - A Study of NX-1607 in Adults With Advanced Malignancies	Phase 1
Completed	`NCT05120167` - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy	N/A
Recruiting	`NCT05483491` - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer	Phase 1
Recruiting	`NCT05736588` - Elimisha HPV (Human Papillomavirus)	N/A
Completed	`NCT05862844` - Promise Women Project	N/A
Recruiting	`NCT04934982` - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)	N/A
Recruiting	`NCT03876860` - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis	N/A
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Completed	`NCT00543543` - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)	Phase 3
Terminated	`NCT04864782` - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer	Phase 2/Phase 3
Recruiting	`NCT04226313` - Self-sampling for Non-attenders to Cervical Cancer Screening	N/A